ITOS vs. APGE, VCEL, BHVN, EWTX, AUPH, CDTX, PAHC, ARDX, TWST, and VERA
Should you be buying iTeos Therapeutics stock or one of its competitors? The main competitors of iTeos Therapeutics include Apogee Therapeutics (APGE), Vericel (VCEL), Biohaven (BHVN), Edgewise Therapeutics (EWTX), Aurinia Pharmaceuticals (AUPH), Cidara Therapeutics (CDTX), Phibro Animal Health (PAHC), Ardelyx (ARDX), Twist Bioscience (TWST), and Vera Therapeutics (VERA). These companies are all part of the "pharmaceutical products" industry.
iTeos Therapeutics vs. Its Competitors
Apogee Therapeutics (NASDAQ:APGE) and iTeos Therapeutics (NASDAQ:ITOS) are both small-cap medical companies, but which is the better investment? We will compare the two companies based on the strength of their earnings, analyst recommendations, institutional ownership, risk, media sentiment, valuation, dividends and profitability.
79.0% of Apogee Therapeutics shares are held by institutional investors. Comparatively, 97.2% of iTeos Therapeutics shares are held by institutional investors. 42.8% of Apogee Therapeutics shares are held by company insiders. Comparatively, 14.2% of iTeos Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.
iTeos Therapeutics has higher revenue and earnings than Apogee Therapeutics. Apogee Therapeutics is trading at a lower price-to-earnings ratio than iTeos Therapeutics, indicating that it is currently the more affordable of the two stocks.
Apogee Therapeutics has a beta of 1.42, suggesting that its stock price is 42% more volatile than the S&P 500. Comparatively, iTeos Therapeutics has a beta of 1.31, suggesting that its stock price is 31% more volatile than the S&P 500.
iTeos Therapeutics' return on equity of -33.26% beat Apogee Therapeutics' return on equity.
Apogee Therapeutics currently has a consensus price target of $97.29, suggesting a potential upside of 157.94%. iTeos Therapeutics has a consensus price target of $15.50, suggesting a potential upside of 52.71%. Given Apogee Therapeutics' stronger consensus rating and higher probable upside, equities analysts clearly believe Apogee Therapeutics is more favorable than iTeos Therapeutics.
In the previous week, iTeos Therapeutics had 1 more articles in the media than Apogee Therapeutics. MarketBeat recorded 1 mentions for iTeos Therapeutics and 0 mentions for Apogee Therapeutics. Apogee Therapeutics' average media sentiment score of 1.11 beat iTeos Therapeutics' score of 0.00 indicating that Apogee Therapeutics is being referred to more favorably in the media.
Summary
Apogee Therapeutics and iTeos Therapeutics tied by winning 7 of the 14 factors compared between the two stocks.
Get iTeos Therapeutics News Delivered to You Automatically
Sign up to receive the latest news and ratings for ITOS and its competitors with MarketBeat's FREE daily newsletter.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding ITOS and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Media Sentiment Over Time
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
iTeos Therapeutics Competitors List
Related Companies and Tools
This page (NASDAQ:ITOS) was last updated on 9/22/2025 by MarketBeat.com Staff
